BillionToOne develops a patented Quantitative Counting Technology (QCT™) molecular counting platform that measures DNA molecules at the single-molecule level. Its oncology liquid biopsy products, Northstar Select® and Northstar Response®, are designed to help clinicians select therapies and monitor treatment response; Northstar Select® offers a 2–5x lower limit of detection versus other assays and Northstar Response® is a methylation-based ctDNA assay with roughly 10x greater precision than SNV-based assays. The company serves both prenatal and oncology markets and intends to use new funding to expand and scale those businesses. BillionToOne reports that over 500,000 patients have received its tests to date. The company has grown from $0M to $125M ARR in the last ~4 years. Its product suite is validated across different cancer types for assessing treatment response in late-stage patients. BillionToOne develops molecular diagnostic tests built on its Quantitative Counting Templates (QCTs) technology. Its UNITY Screen is a non-invasive prenatal test (NIPT) that assesses fetal risk for recessive conditions and red blood cell antigen incompatibility, in addition to aneuploidies. The company also plans to commercialize a liquid biopsy product line—Northstar Select and Northstar Response—in early 2023. BillionToOne intends to use newly raised capital to continue scaling the UNITY Screen and advance commercialization of the Northstar products. The company is led by CEO Oguzhan Atay and is based in Menlo Park, CA. The article does not report operating metrics such as revenue or user counts. BillionToOne is a Menlo Park, CA-based molecular diagnostics company focused on making molecular diagnostics more accurate, efficient, and accessible. Its QCT molecular counter platform can count DNA molecules at the single-count level with single base-pair precision. The company’s flagship UNITY Screen™ is a non-invasive prenatal test (NIPT) that assesses fetal risk for common recessive conditions and aneuploidies from a single maternal blood sample. UNITY Screen™ does not require a paternal sample, supporting greater equity in care. BillionToOne plans to use new funds to expand commercial and clinical teams, scale lab capacity, and conduct clinical studies for its liquid biopsy test. The company was co-founded by Oguzhan Atay, Ph.D., and David Tsao, Ph.D. BillionToOne is a Menlo Park, Calif.-based molecular diagnostics company that develops precision diagnostics using its patent-pending QCT molecular counter platform. The QCT platform can count DNA molecules at single-count resolution. Its flagship product, UNITY, is a noninvasive prenatal screening test of fetal cell-free DNA for cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies through maternal blood. The company closed a $55M Series B in June 2021 and intends to use the funds to expand its clinical lab and grow its commercial team nationwide. The round was led by existing investor Hummingbird Ventures and incoming investor Four Rivers Group, with participation from Neotribe Ventures, Norwest Venture Partners, Y Combinator, and Libertus Capital. BillionToOne was co-founded by Oguzhan Atay, Ph.D., and David Tsao, Ph.D., and is also led by Jennifer Hoskovec, MS, CGC, Director of Medical Affairs. BillionToOne, Inc., based in Menlo Park, Calif., is a precision diagnostics company that invented the patent-pending QCT™ molecular counter platform. Its core product, UNITY™, is a prenatal screen that directly assesses a fetus's risk for inherited disorders such as cystic fibrosis, spinal muscular atrophy (SMA), and hemoglobinopathies from a single tube of maternal blood. UNITY™ is available for commercial order in all US states except New York and in select international countries. The company is led by co-founder and CEO Oguzhan Atay, Ph.D. BillionToOne closed a follow-on Series A+ funding round of $15M, bringing total funding to more than $32.5M. The company plans to use the proceeds to support commercial expansion of UNITY across the US and to fund R&D of future diagnostics tests, including liquid biopsy products.

Total raised

$424M

Funding rounds

7

Latest round

Series D

Latest activity

Jun 2024